Davidson Trust Co. Acquires 195 Shares of Amgen Inc. (NASDAQ:AMGN)

Davidson Trust Co. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 11.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,928 shares of the medical research company’s stock after buying an additional 195 shares during the quarter. Davidson Trust Co.’s holdings in Amgen were worth $555,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the business. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Amgen by 1.7% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock worth $3,133,000 after acquiring an additional 193 shares during the last quarter. Diversified Trust Co lifted its holdings in Amgen by 76.8% during the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after buying an additional 16,376 shares in the last quarter. Nicolet Advisory Services LLC lifted its holdings in Amgen by 4.4% during the 3rd quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after buying an additional 117 shares in the last quarter. Platform Technology Partners lifted its holdings in Amgen by 7.4% during the 3rd quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock valued at $1,567,000 after buying an additional 402 shares in the last quarter. Finally, Traynor Capital Management Inc. lifted its holdings in Amgen by 9.5% during the 4th quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock valued at $5,455,000 after buying an additional 1,650 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. The Goldman Sachs Group lifted their price objective on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. SVB Leerink cut shares of Amgen from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $324.00 to $318.00 in a research note on Wednesday, February 7th. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and boosted their target price for the company from $264.00 to $320.00 in a research note on Thursday, December 21st. Finally, Truist Financial reiterated a “buy” rating and issued a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Ten investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and an average price target of $296.95.

Amgen Trading Up 1.5 %

Shares of AMGN traded up $4.04 during mid-day trading on Friday, reaching $266.79. The stock had a trading volume of 838,191 shares, compared to its average volume of 2,824,583. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The business’s fifty day moving average is $277.34 and its 200 day moving average is $281.24. The firm has a market cap of $142.98 billion, a price-to-earnings ratio of 21.22, a P/E/G ratio of 2.46 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the prior year, the business posted $4.09 EPS. On average, sell-side analysts predict that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.37%. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.